Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Yellow Fever

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dengue

Conditions

Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Yellow Fever

Trial Timeline

Dec 6, 2011 → Sep 27, 2013

NCT ID

NCT01488890

About Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Yellow Fever

Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Yellow Fever is a phase 2 stage product being developed by Sanofi for Dengue. The current trial status is completed. This product is registered under clinical trial identifier NCT01488890. Target conditions include Dengue, Dengue Fever, Dengue Hemorrhagic Fever.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01488890	Phase 2	Completed	Dec 6, 2011	Sep 27, 2013	Dengue

Competing Products

20 competing products in Dengue

See all competitors

Product	Company	Stage	Hype Score
V180 + Alhydrogel™ + Placebo	Merck	Phase 1	33
Low-dose V180 with low-dose ISCOMATRIX™ adjuvant + Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant + Medium-dose V180 (non-adjuvanted) + Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant + Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant + Medium-dose V180 with Alhydrogel™ adjuvant + High-dose V180 (non-adjuvanted) + High-dose V180 with low-dose ISCOMATRIX™ adjuvant + High-dose V180 with medium-dose ISCOMATRIX™ adjuvant + Low-dose V180 with high-dose ISCOMATRIX™ adjuvant + Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant + High-dose V180 with high-dose ISCOMATRIX™ adjuvant + Placebo	Merck	Phase 1	33
V181 + Butantan - DV	Merck	Phase 2	52
V181 High-Potency Level + V181 Mid-Potency Level + V181 Low-Potency Level + Placebo	Merck	Phase 2	52
EYU688 + Placebo	Novartis	Phase 2	52
balapiravir [RO4588161] + placebo	Roche	Phase 1	33
Dengue Tetravalent Vaccine, Live	Sanofi	Pre-clinical	22
CYD Dengue Vaccine (5-dose formulation) + Placebo, NaCl 0.9%	Sanofi	Phase 2	51
Chimeric dengue serotype (1, 2, 3, 4) + Chimeric dengue serotype (1, 2, 3, 4) + Chimeric dengue serotype (1, 2, 3, 4)	Sanofi	Phase 2	51
Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Placebo: NaCl 0.9%	Sanofi	Phase 3	76
Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus + NaCl 0.9% + Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed + Meningococcal A+C vaccine	Sanofi	Phase 2	51
Tetravalent CYD Dengue Vaccine , 5555 formulation + Tetravalent CYD Dengue Vaccine , 5553 formulation + Tetravalent CYD Dengue Vaccine, 4444 formulation	Sanofi	Phase 2	51
CYD Dengue Vaccine + Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed + Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed	Sanofi	Phase 3	76
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Placebo: NaCl 0.9%	Sanofi	Phase 3	76
Live, attenuated, dengue serotype 1, 2, 3, 4 virus + Placebo: (NaCl) 0.9% solution	Sanofi	Phase 3	76
CYD Dengue Vaccine + CYD Dengue Vaccine + Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.	Sanofi	Phase 3	76
CYD dengue vaccine serotypes (1, 2, 3, 4). + Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide	Sanofi	Phase 2	51
CYD Dengue Vaccine + Placebo (Sodium chloride 0.9%)	Sanofi	Phase 2	51
CYD Dengue Vaccine + Inactivated rabies virus vaccine + Placebo	Sanofi	Phase 2	51
Live, attenuated, dengue serotype 1, 2, 3, 4 virus + Placebo: Sodium chloride (NaCl) 0.9%	Sanofi	Phase 3	76

Other Products from Sanofi

Adacel®Approved

LACTIC ACID(ND)Approved

DupilumabApproved

glatiramer acetateApproved

INSULIN GLULISINE + INSULIN GLARGINEApproved